51 related articles for article (PubMed ID: 16632461)
1. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations.
Smith DE; Jeganathan S; Ray J
HIV Clin Trials; 2006; 7(1):34-8. PubMed ID: 16632461
[TBL] [Abstract][Full Text] [Related]
2. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.
Kiser JJ; Rutstein RM; Samson P; Graham B; Aldrovandi G; Mofenson LM; Smith E; Schnittman S; Fenton T; Brundage RC; Fletcher CV
AIDS; 2011 Jul; 25(12):1489-96. PubMed ID: 21610486
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients.
Goutelle S; Baudry T; Gagnieu MC; Boibieux A; Livrozet JM; Peyramond D; Chidiac C; Tod M; Ferry T;
Antimicrob Agents Chemother; 2013 Jan; 57(1):517-23. PubMed ID: 23147727
[TBL] [Abstract][Full Text] [Related]
4. Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.
Moyle G; Else L; Jackson A; Back D; Yapa MH; Seymour N; Ringner-Nackter L; Karolia Z; Gazzard B; Boffito M
Antimicrob Agents Chemother; 2013 Aug; 57(8):3640-4. PubMed ID: 23689708
[TBL] [Abstract][Full Text] [Related]
5. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.
Siccardi M; D'Avolio A; Baietto L; Gibbons S; Sciandra M; Colucci D; Bonora S; Khoo S; Back DJ; Di Perri G; Owen A
Clin Infect Dis; 2008 Nov; 47(9):1222-5. PubMed ID: 18831695
[TBL] [Abstract][Full Text] [Related]
6. A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents.
Ngara B; Zvada S; Chawana TD; Stray-Pedersen B; Nhachi CFB; Rusakaniko S
BMC Pharmacol Toxicol; 2020 Aug; 21(1):58. PubMed ID: 32746923
[TBL] [Abstract][Full Text] [Related]
7. Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.
Venuto CS; Lim J; Messing S; Hunt PW; McComsey GA; Morse GD
Antivir Ther; 2018; 23(4):345-351. PubMed ID: 29171837
[TBL] [Abstract][Full Text] [Related]
8. Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation.
Leger P; Chirwa S; Nwogu JN; Turner M; Richardson DM; Baker P; Leonard M; Erdem H; Olson L; Haas DW
Pharmacogenet Genomics; 2018 Jan; 28(1):1-6. PubMed ID: 29117017
[TBL] [Abstract][Full Text] [Related]
9. A Genome-Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair.
Tamraz B; Huang Y; French AL; Kassaye S; Anastos K; Nowicki MJ; Gange S; Gustafson DR; Bacchetti P; Greenblatt RM; Hysi PG; Aouizerat BE
Clin Pharmacol Ther; 2018 Nov; 104(5):949-956. PubMed ID: 29315502
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease.
Mahdi M; Mótyán JA; Szojka ZI; Golda M; Miczi M; Tőzsér J
Virol J; 2020 Nov; 17(1):190. PubMed ID: 33243253
[TBL] [Abstract][Full Text] [Related]
11. Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.
Crane HM; Nance RM; Heckbert SR; Ritchings C; Rosenblatt L; Budoff M; Wood BR; Tirschwell DL; Kim HN; Mathews WC; Geng E; Moore RD; Hunt PW; Eron JJ; Burkholder GA; Drozd DR; Chow FC; Becker KJ; Zunt JR; Ho EL; Kalani R; Huffer A; Whitney BM; Saag MS; Kitahata MM; Delaney JAC
J Acquir Immune Defic Syndr; 2019 Aug; 81(5):e141-e147. PubMed ID: 31135582
[TBL] [Abstract][Full Text] [Related]
12. Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV.
Waalewijn H; Turkova A; Rakhmanina N; Cressey TR; Penazzato M; Colbers A; Burger DM;
Ther Drug Monit; 2019 Aug; 41(4):431-443. PubMed ID: 31008997
[TBL] [Abstract][Full Text] [Related]
13. Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study.
Nsanzimana S; Semakula M; Ndahindwa V; Remera E; Sebuhoro D; Uwizihiwe JP; Ford N; Tanner M; Kanters S; Mills EJ; Bucher HC
BMC Infect Dis; 2019 Apr; 19(1):312. PubMed ID: 30953449
[TBL] [Abstract][Full Text] [Related]
14. No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
Gutierrez-Valencia A; García C; Viciana P; Milanés-Guisado Y; Fernandez-Magdaleno T; Espinosa N; Pasquau J; López-Cortés LF
PLoS One; 2018; 13(9):e0203452. PubMed ID: 30235244
[TBL] [Abstract][Full Text] [Related]
15. Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.
Daudon M; Frochot V; Bazin D; Jungers P
Drugs; 2018 Feb; 78(2):163-201. PubMed ID: 29264783
[TBL] [Abstract][Full Text] [Related]
16. A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.
Ongubo DM; Lim R; Tweya H; Stanley CC; Tembo P; Broadhurst R; Gugsa S; Ngongondo M; Speight C; Heller T; Phiri S; Hosseinipour MC
BMC Infect Dis; 2017 Jul; 17(1):461. PubMed ID: 28673254
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.
Moltó J; Estévez JA; Miranda C; Cedeño S; Clotet B; Valle M
Br J Clin Pharmacol; 2016 Dec; 82(6):1528-1538. PubMed ID: 27447851
[TBL] [Abstract][Full Text] [Related]
18. Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
Gervasoni C; Meraviglia P; Minisci D; Ferraris L; Riva A; Landonio S; Cozzi V; Charbe N; Molinari L; Rizzardini G; Clementi E; Galli M; Cattaneo D
PLoS One; 2015; 10(4):e0123670. PubMed ID: 25875091
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study.
Lafaurie M; De Sousa B; Ponscarme D; Lapidus N; Daudon M; Weiss L; Rioux C; Fourn E; Katlama C; Molina JM
PLoS One; 2014; 9(11):e112836. PubMed ID: 25409506
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
